Skip to main content
ImmuneCited

Omega-3 Fatty Acids (EPA/DHA) for Autoimmune Conditions

B

The VITAL trial showed a 15% reduction in autoimmune disease risk with omega-3 supplementation. Additional clinical trials demonstrate benefits for supporting balanced inflammatory responses in rheumatoid arthritis and inflammatory bowel disease.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dautoimmune\u002Dconditions'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

The Bottom Line

The VITAL trial showed a 15% reduction in autoimmune disease risk with omega-3 supplementation. Additional clinical trials demonstrate benefits for supporting balanced inflammatory responses in rheumatoid arthritis and inflammatory bowel disease.

Key Study Findings

Review
Impact of Nutritional Diet Therapy on Rheumatoid Arthritis Disease Activity.
Dose: None vs: None Outcome: rheumatoid arthritis disease activity modulation through diet Effect: None None

Population: patients with rheumatoid arthritis

Case Reports n=1
GPIHBP1 Autoantibody-Related Hypertriglyceridemia in a 12-Year-Old Girl With Systemic Lupus Erythematosus.
Dose: None vs: None Outcome: GPIHBP1 autoantibody and LPL mass normalization Effect: None None

Population: 12-year-old girl with SLE and severe hypertriglyceridemia

Review
Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and …
Dose: None vs: None Outcome: Epigenetic and mitochondrial modulation in MS Effect: None None

Population: Multiple sclerosis patients (review)

Review
The Role of Nutrition in the Development, Management, and Prevention of Rheumatoid Arthritis: A Comprehensive …
Dose: None vs: None Outcome: RA risk and disease activity Effect: None None

Population: Patients with rheumatoid arthritis

Review
Specialized pro-resolving mediators and autoimmunity: Recent insights and future perspectives.
Dose: None vs: None Outcome: None Effect: None None

Population: None

Systematic Review
Modulating inflammation and oxidative stress in rheumatoid arthritis: a systematic review of nutraceutical interventions.
Dose: None vs: None Outcome: None Effect: None None

Population: Systematic review of nutraceuticals in rheumatoid arthritis

Key Statistics

10

Studies

25000

Participants

Positive

B

Grade

Referenced Papers

BMJ (Clinical research … 2022 9 citations
Current atherosclerosis reports 2004 464 citations
Journal of the … 2002 2016 citations
Biochemical Society transactions 1995 15 citations
World review of … 1994 8 citations
The American journal … 1991 2278 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

general:
250-500 mg combined EPA/DHA/day
antiinflammatory:
1,000-3,000 mg combined EPA/DHA/day

Upper limit: 3,000 mg/day EPA+DHA (FDA-recognized as safe)

Dosages Studied in Research

Dosage Duration Effect N
None -- Positive --
None -- Positive 1
None -- Positive --
None -- Positive --
None -- Mixed --
None -- Mixed --
None -- Positive --
None -- Neutral --

Best taken: With meals

Safety & Side Effects

Reported Side Effects

  • Fishy aftertaste and burping
  • Gastrointestinal discomfort (nausea, diarrhea)
  • Increased bleeding risk at high doses
  • Potential LDL cholesterol increase at very high doses

Known Interactions

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk)
  • Blood pressure medications (additive blood pressure lowering)
  • Orlistat (may reduce omega-3 absorption)
  • Cyclosporine (may modify immunosuppressive effects)

Tolerable upper intake: 3,000 mg/day EPA+DHA (FDA-recognized as safe)

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Autoimmune Conditions?
Based on 10 studies with 25,000 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (EPA/DHA) may support Autoimmune Conditions management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Autoimmune Conditions?
Studies have used various dosages. A commonly studied range is 250-500 mg combined EPA/DHA/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Gastrointestinal discomfort (nausea, diarrhea), Increased bleeding risk at high doses, Potential LDL cholesterol increase at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Autoimmune Conditions?
We rate the evidence as Grade B (Good Evidence). This rating is based on 10 peer-reviewed studies with 25,000 total participants. The overall direction of effect is positive.

Related Evidence

Other ingredients for Autoimmune Conditions

Omega-3 Fatty Acids (EPA/DHA) for other conditions

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.